RxDoctor Payments Data

Manoher Gurru, MD

Sleep Medicine · Midland, TXNPI 1558394601

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,179 of the $7,533 with a category attached, or 82.0%. 43 manufacturers reported payments, led by AbbVie at 26.6% of the total.

$7,533in general payments, 2019–2025

Across 351 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • MDD US Operations, LLC$853
  • Resmed Corp$480
  • Inspire Medical Systems, Inc.$384
  • Bristol Myers Squibb$374
  • Biogen$319
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$71810%
  • Food & beverage$6,17982%
  • Education$1552%
  • Gifts$4806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,533 in reported general payments places this provider in the 80th percentile of 112 sleep medicine providers in Texas.

See all sleep medicine providers in Texas

Medicare billing

Part B allowed, 2024
$266,302
Medicare patients
634
Services billed
6,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4644$394,148
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$137,374
NamzaricMemantine Hcl/Donepezil Hcl50$36,863
BriviactBrivaracetam19$29,909
EliquisApixaban21$20,254
UbrelvyUbrogepant14$16,499
Emgality PenGalcanezumab-Gnlm16$15,368
Nurtec OdtRimegepant Sulfate11$12,087
Aimovig AutoinjectorErenumab-Aooe14$10,297
Carbamazepine ErCarbamazepine92$6,870
Gabapentin293$4,865
Memantine Hcl245$4,649
Lacosamide55$3,727
Levetiracetam126$3,451
Duloxetine Hcl132$2,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$19$394,14844 claims
CSL BehringPrivigen$114$137,37413 claims
AbbVieNamzaric, Ubrelvy$2,006$53,36364 claims
PfizerEliquis, Nurtec Odt$190$32,34032 claims
UCB, Inc.Briviact$157$29,90919 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$50$1,02316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 sleep medicine providers in Texas.

Other sleep medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →